Catalent Implements Optofluidic Platform for Cell-Line Development
Pharmaceutical Technology's In the Lab eNewsletter
Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.
Catalent Pharma Solutions and Berkeley Lights announced in a July 10, 2018 press release that Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.
The Beacon platform is capable of screening thousands of clones in parallel and identifying top-producing clones in five days. According to Catalent, automating the process on the platform provides additional insights into the behavior of clonal populations that are currently unavailable using traditional techniques.
The four integrated workflows of the platform-import, culture, assay, and export-will be applied to Catalent Biologics’ GPEx cell-line development platform as well as Catalent’s ongoing research and development activities.
Source: Catalent Pharma Solutions
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
